Pharmacokinetics and Therapeutic Drug Monitoring of Immunosuppressants

Advances in Chromatographic Techniques for Therapeutic Drug Monitoring

Volumn , Issue , 2009, Pages 209-238

  Kelly, Kathleen A ^a   Butch, Anthony W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85112436834     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9781420067590-19     Document Type: Chapter

References (229)

1. Merrill JP, Murray JE, Harrison JH, Guild WR. 1956. Successful homotransplantation of the human kidney between identical twins. JAMA 160: 277-82.
2. Murray JE, Merrill JP, Harrison JH, Wilson RE, Dammin GJ. 1963, Prolonged survival of human-kidney homographs by immunosuppressive drug therapy. N Engl J Med 268: 1315-23.
3. Starzl TE, Marchioro TL, Waddell WR. 1963. The reversal of rejection in human renal homografts with subsequent development of homograft tolerance. Surg Gynecol Obstet 117: 385-95.
4. Calne RY, White DJ, Thiru S, Evans DB, McMaster P, Dunn DC, Craddock GN, Pentlow BD, Rolles K. 1978. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 2: 1323-27.
5. Goto T, Kino T, Hatanaka H, Nishiyama M, Okuhara M, Kohsaka M, Aoki H, Imanaka H. 1987. Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. Transplant Proc 19: 4-8.
6. Singh K, Sun S, Vezina C. 1979. Rapamycin (AY-22, 989), a new antifungal antibiotic. IV. Mechanism of action. J Antibiot (Tokyo) 32: 630-45.
7. Sollinger HW. 1995. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 60: 225-32.
8. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. 1996. A blind, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 61: 1029-37.
9. European Mycophenolate Mofetil Cooperative Study Group. 1995. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 345: 1321-25.
10. Scientific Registry of Transplant Recipients. Trends in organ organ donation and transplantation in the United States, 1997-2007. Table I-1. http://www.ustransplant.org/annual_reports/current/Chapter_I_ AR_CD.htm?cp =2 (Accessed November 2008).
11. Scientific Registry of Transplant Recipients. Trends in organ organ donation and transplantation in the United States, 1997-2007. Table I-3. http://www.ustransplant.org/annual_reports/current/Chapter_I_ AR_CD.htm?cp =2 (Accessed November 2008).
12. Lindholm A, Albrechtsen D, Tufveson G, Karlberg I, Persson NH, Groth CG. 1992. A randomized trial of cyclosporine and prednisolone versus cyclosporine, azathioprine, and prednisolone in primary cadaveric renal transplantation. Transplantation 54: 624-31.
13. Anon. 1983. Cyclosporin in cadaveric renal transplantation: one-year follow-up of a multicentre trial. Lancet 2: 986-89.
14. Bruunshuus I, Schmiegelow K. 1989. Analysis of 6-mercaptopurine, 6-thioguanine nucleotides and 6-thiuric acid in biological fluids by high-performance liquid chromatography. Scand J Clin Invest 49: 779-84.
15. Kreuzenkamp-Jansen CW, De Abreu RA, Bokkerink JPM, Trijbels JMF. 1995. Determination of extracellular and intracellular thiopurines and methylthiopurines with HPLC. J Chromatogr 672: 53-61.
16. Rabel SR, Stobaugh JF, Trueworthy R. 1995. Determination of intracellular levels of 6-mercaptopurine metabolites in erythrocytes utilizing capillary electrophoresis with laser-induced fluorescence detection. Anal Biochem 224: 315-22.
17. Filler G, Lepage N, Delisle B, Mai I. 2001. Effect of cyclosporine on mycophenolic acid area under the concentration-curve in pediatric kidney transplant recipients. Ther Drug Monit 23: 514-19.
18. van Gelder T, Klupp J, Barten MJ, Christians U, Morris RE. 2001. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 23: 119-28.
19. Undre NA. 2003. Pharmacokinetics of tacrolimus-based combination therapies. Nephrol Dial Transplant 18(Suppl 1): i12-i15.
20. Scientific Registry of Transplant Recipients. Trends in organ donation and transplantation in the United States, 1997-2007. Table III-2. http://www.ustransplant.org/annual_reports/archives/2005/Chapter_III_ AR_CD.htm?cp =4 (Accessed November 2008)
21. Shibasaki F, Hallin U, Uchino H. 2002. Calcineurin as a multifunctional regulator. J Biochem (Tokyo) 131: 1-15.
22. Siekierka JJ, Hung SH, Poe M, Lin CS, Sigal NH. 1989. A cytosolic binding protein for the immunosuppressant FK506 has peptidylprolyl isomerase activity but is distinct from cyclophilin. Nature 341: 755-57.
23. Schreiber SL, Crabtree GR. 1992. The mechanism of action of cyclosporin A and FK-506. Immunol Today 13: 136-42.
24. Flanagan WM, Corthesy B, Bram RJ, Crabtree GR. 1991. Nuclear association of a T-cell transcription factor blocked by FK506 and cyclosporin A. Nature 352: 803-7.
25. Clipstone NA, Crabtree GR. 1992. Identification of calcineurin as a key signaling enzyme in T-lymphocyte activation. Nature 357: 695-97.
26. Schreiber SL. 1991. Chemistry and biology of immunophilins and their immunosuppressive ligands. Science 251: 283-87.
27. Gummert JF, Ikonen T, Morris RE. 1999. Newer immunosuppressive drugs: a review. J Am Soc Nephrol 10: 1366-80.
28. Jorgensen KA, Koefoed-Nielsen PB, Karamperis N. 2003. Calcineurin phosphatase activity and immunosuppression. A review on the role of calcineurin phosphatase activity and the immunosuppressive effect of cyclosporin A and tacrolimus. Scand J Immunol 57: 93-98.
29. Borel JF, Feurer C, Gubler HU, Stahelin H. 1976. Biological effects on cyclosporin A: a new antilymphocytic agent. Agents and Actions 6: 468-75.
30. Vonderscher J, Meinzer A. 1994. Rationale for the development of Sandimmune Neoral. Transplant Proc 26: 2925-27.
31. Bartucci MR. 1999. Issues in cyclosporine drug substitution: implications for patient management. J Transpl Coord 9: 137-42.
32. Alloway RR. 1999. Generic immunosuppressant use in solid organ transplantation. Transplant Proc 31(Suppl 3A): 2S-5S.
33. Kovarik JM, Mueller EA, van Bree JB, Fluckinger SS, Lange H, Schmidt B, Boesken WH, Lison AE, Kutz K. 1994. Cyclosporine pharmacokinetics and variability from a microemulsion formulation-a multicenter investigation in kidney transplant patients. Transplantation 58: 658-63.
34. Ptachcinski RJ, Venkataramanan R, Burckart GJ. 1986. Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinet 11: 107-32.
35. Hoppu K, Jalanko H, Laine J, Holmberg C. 1996. Comparison of conventional oral cyclosporine and cyclosporine microemulsion formulation in children with a liver transplant. Transplantation 62: 66-71.
36. Faulds D, Goa KL, Benfield P. 1993. Cyclosporin. A review of its pharmacodynamic and pharmacotherapeutic properties, and therapeutic use in immunoregulatory disorders. Drugs 45: 953-1040.
37. Noble S, Markham A. 1995. Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral). Drugs 50: 924-41.
38. Fahr A. 1993. Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet 24: 472-95.
39. Wenk M, Follath F, Abisch E. 1983. Temperature dependency of apparent cyclosporine A concentrations in plasma. Clin Chem 29: 1865.
40. Kahan BD, Shaw LM, Holt D, Grevel J, Johnston A. 1990. Consensus document: Hawk’s meeting on therapeutic drug monitoring of cyclosporine. Clin Chem 36: 1510-16.
41. Shaw LM, Yatscoff RW, Bowers LD, Freeman DJ, Jeffery JR, Keown PA, McGilveray IJ, Rosano TG, Wong PY. 1990. Canadian consensus meeting on cyclosporine monitoring: Report of the consensus panel. Clin Chem 36: 1841-46.
42. Ollerich M, Armstrong VW, Kahan B, Shaw L, Holt DW, Yatscoff R, Lindholm A, Halloran P, Gallicano K, Wonigeit K, Schutz E, Schran H, Annesley T. 1995. Lake Louise consensus conference on cyclosporin monitoring in organ transplantation: report of the consensus panel. Ther Drug Monit 17: 642-54.
43. Zhang YC, Benet L. 2001. The gut as a barrier to drug absorption. Clin Pharmacokinet 40: 159-68.
44. Wu CY, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY, Wacher VJ. 1995. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 58: 492-97.
45. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ, Watkins PB. 1997. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 62: 248-60.
46. Wallemacq PE, Lhoest G, Dumont P. 1989. Isolation, purification and structure elucidation of cyclosporine A metabolites in rabbit and man. Biomed Mass Spectrom 18: 48-56.
47. Chrintians U, Sewing KF. 1993. Cyclosporin metabolism in transplant patients. Pharmacol Ther 57: 291-345.
48. Yatscoff RW, Rosano TG, Bowers LD. 1991. The clinical significance of cyclosporine metabolites. Clin Biochem 24: 23-35.
49. Radeke HH, Christians U, Sewing KF, Resch K. 1992. The synergistic immunosuppressive potential of cyclosporin metabolite combinations. Int J Immunopharmacol 14: 595-604.
50. Rosano TG, Brooks CA, Dybas MT, Cramer SM, Stevens C, Freed BM. 1990. Selection of an optimal assay method for monitoring cyclosporine therapy. Transplant Proc 22: 1125-28.
51. Ryffel B, Foxwell BM, Mihatsch MJ, Donatsch P, Maurer G. 1988. Biologic significance of cyclosporine metabolites. Transplant Proc 20(suppl 2): 575-84.
52. Smets F, Sokal EM. 2002. Lymphoproliferation in children after liver transplantation. J Pediatr Gastroenterol Nutr 34: 499-505.
53. Scott JP, Higenbottam TW. 1988. Adverse reactions and interactions of cyclosporin. Med Toxicol 3: 107-27.
54. Yee GC, McGuire TR. 1990. Pharmacokinetic drug interactions with cyclosporin. Clin Pharmacol 19: 319-32 and 400-15.
55. Durr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K. 2000. St. John’s Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 68: 598-604.
56. Smith MC, Sephel GC. 1990. Long-term in vitro stability of cyclosporine in whole-blood samples. Clin Chem 36: 1991-92.
57. Schran HF, Rosano TG, Hasse AE, Pell MA. 1987. Determination of cyclosporine concentrations with monoclonal antibodies. Clin Chem 33: 2225-29.
58. Keown P, Landsberg D, Hollaran P, Shoker A, Rush D, Jeffery J et al. 1996. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group. Transplantation 27: 1744-52.
59. Halloran PF, Helms LM, Noujaim J. 1999. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation 15: 1356-61.
60. Lindholm A, Kahan BD. 1993. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 54: 205-18.
61. Lindholm A. 1991. Review: factors influencing the pharmacokinetics of cyclosporine in man. Ther Drug Monit 13: 465-77.
62. Grevel J, Welsh MS, Kahan B. 1989. Cyclosporine monitoring in renal transplantation: area under the curve monitoring is superior to trough-level monitoring. Ther Drug Monit 11: 246-48.
63. Belitsky P, Levy GA, Johnston A. 2000. Neoral absorption profiling: an evolution in effectiveness. Transplant Proc 32(suppl 3A): S45-S52.
64. Keown P, Niese D. 1998. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmune Neoral Study Group. Kidney Int 54: 938-44.
65. Stein CM, Murray JJ, Wood AJ. 1999. Inhibition of stimulated interleukin-2 production in whole blood: a practical measure of cyclosporine effect. Clin Chem 45: 1477-84.
66. Oellerick M, Armstrong VW. 2002. Two-hour cyclosporine concentration determination: an appropriate tool to monitor neoral therapy? Ther Drug Monit 24: 40-46.
67. Mahalati K, Belitsky P, Sketris I, West K, Panek R. 1999. Neoral monitoring by simplified sparse sampling area under the concentration-time curve. Transplantation 68: 55-62.
68. Grant D, Kneteman N, Tchervenkow J, Roy A, Murphy G, Tan A, Hendricks L, Guilbault N, Levy G. 1999. Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of neoral and sandimmune for liver transplantation (NOF-8). Transplantation 67: 1133-37.
69. Cantarovick M, Barkun JS, Tchervenkov JI, Besner JG, Aspeslet L, Metrakos P. 1998. Comparison of Neoral dose monitoring with cyclosporine through levels versus 2-hour postdose levels in stable liver transplant patients. Transplantation 66: 1621-27.
70. Cantarovick M, Elstein E, de Varennes B, Barkun JS. 1999. Clinical benefit of Neoral dose monitoring with cyclosporine 2-hour post-dose levels compared with trough levels in stable heart transplant patients. Transplantation 68: 1839-42.
71. Knight SR, Morris PJ. 2007. The clinical benefits of cyclosporine C2-level monitoring: a systemic review. Transplantation 83: 1525-35.
72. Wallemacq PE. 2004. Therapeutic monitoring of immunosuppressant drugs. Where are we? Clin Chem Lab Med 42: 1204-11.
73. Whitman DA, Abbott V, Fregien K, Bowers LD. 1993. Recent advances in high-performance liquid chromatography/mass spectrometry and high-performance liquid chromatography/tandem mass spectrometry: detection of cyclosporine and metabolites in kidney and liver tissue. Ther Drug Monit 15: 552-56.
74. Zhou L, Tan D, Theng J, Lim L, Liu YP, Lam KW. 2001. Optimized analytical method for cyclosporine A by high-performance liquid chromatography-electrospray ionization mass spectrometry. J Chromatogr B Biomed Sci Appl 754: 201-7.
75. Taylor PJ. 2004. Therapeutic drug monitoring of immunosuppressant drugs by high-performance liquid chromatography-mass spectrometry. Ther Drug Monit 26: 215-19.
76. ® cyclosporine assay: an analytical evaluation. Clin Chem 52(suppl): A60 (abstract).
77. Maine GT, Wallemacq P, Ait-Youcet H, Berg K, Schmidt E, Young J et al. 2008. Analytical multi-site evaluation of the Abbott ARCHITECT cyclosporine assay. Clin Chem 54(suppl): A13 (abstract).
78. Tredger JM, Roberts N, Sherwood R, Higgins G, Keating J. 2000. Comparison of five cyclosporin immunoassays with HPLC. Clin Chem Lab Med 38: 1205-7.
79. Steimer W. 1999. Performance and specificity of monoclonal immunoassays for cyclosporine monitoring: how specific is specific? Clin Chem 45: 371-81.
80. Schutz E, Svinarov D, Shipkova M, Niedmann PD, Armstrong VW, Wieland E, Oellerich M. 1998. Cyclosporin whole blood immunoassays (AxSYM, CEDIA, and Emit): a critical overview of performance characteristics and comparison with HPLC. Clin Chem 44: 2158-64.
81. Hamwi A, Veitl M, Manner G, Ruzicka K, Schweiger C, Szekeres T. 1999. Evaluation of four automated methods for determination of whole blood cyclosporine concentrations. Am J Clin Pathol 112: 358-65.
82. Terrell AR, Daly TM, Hock KG, Kilgore DC, Wei TQ, Hernandez S, Weibe D. 2002. Evaluation of a no-pretreatment cyclosporin A assay on the Dade Behring Dimension RxL clinical analyzer. Clin Chem 48: 1059-65.
83. ® cyclosporine PLUS whole blood immunoassay. J Anal Toxicol 28: 204-10.
84. Analytical Services International. Ciclosporin International Proficiency Testing Scheme. http://www. bioanalytics.co.uk/pt/dates_and_results/Cic295.pdf (Accessed November 2008).
85. Morris RG, Holt DW, Armstrong VW, Griesmacher A, Napoli KL, Shaw LM. 2004. Analytical aspects of cyclosporine monitoring, on behalf of the IFCC/IATDMCT joint working group. Ther Drug Monit 26: 227-30.
86. Holt DW, Johnston A, Kahan BD, Morris RG, Oellerich M, Shaw LM. 2000. New approaches to cyclosporine monitoring raise further concerns about analytical techniques. Clin Chem 46: 872-74.
87. Juenke JM, Brown PI, Urry FM, McMillin GA. 2004. Specimen dilution for C2 monitoring with the Abbott TDxFLx cyclosporine monoclonal whole blood assay. Clin Chem 50: 1430-3.
88. Johnston A, Chusney G, Schutz E, Oellerich M, Lee TD, Holt DW. 2003. Monitoring cyclosporin in blood: between-assay differences at trough and 2 hours post-dose (C2). Ther Drug Monit 25: 167-73.
89. First MR. 2004. Tacrolimus based immunosuppression. J Nephrol 17: 25-31.
90. Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, McMichael J. 1995. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 29: 404-30.
91. Zahir H, Nand RA, Brown KF, Tattam BN, McLachlan AJ. 2001. Validation of methods to study the distribution and protein binding of tacrolimus in human blood. J Pharmacol Toxicol Methods 46: 27-35.
92. Iwasaki K, Shiraga T, Nagase K, Tozuka Z, Noda K, Sakuma S, Fujitsu T. 1993. Isolation, identification, and biological activities of oxidative metabolites of FK506, a potent immunosuppressive macrolide lactone. Drug Metab Dispos 21: 971-77.
93. Kelly P, Kahan BD. 2002. Review: metabolism of immunosuppressant drugs. Curr Drug Metab 3: 275-87.
94. Tamura K, Fujimura T, Iwasaki K, Sakuma S, Fujitsu T, Nakamura K. et al. 1994. Interaction of tacrolimus (FK506) and its metabolites with FKBP and calcineurin. Biochem Biophys Res Commun 202: 437-43.
95. Beysens J, Wigner RMH, Beuman GH, van der Heyden J, Kootstra G, van As H. 1991. FK 506: Monitoring in plasma or in whole blood? Transplant Proc 23: 2745-47.
96. Taylor AL, Watson CJE, Bradley JA. 2005. Immunosuppressive agents in solid organ transplantation: mechanisms of action and therapeutic efficacy. Crit Rev Oncol/Hematol 56: 23-46.
97. Artz MA, Boots JM, Ligtenberg G, Roodnat JI, Christiaans MH, Vos PF, Moons P et al. 2004. Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. Am J Transplant 4: 937-45.
98. Mentzer Jr RM, Jahania MS, Lasley RD. 1998. Tacrolimus as a rescue immunosuppressant after heart and lung transplantation. The U.S. Multicenter FK506 Study Group. Transplantation 65: 109-13.
99. Laskow DA, Neylan JF, Shapiro RS, Pirsch JD, Vergne-Marini PJ, Tomlanovich SJ. 1998. The role of tacrolimus in adult kidney transplantation: a review. Clin Tranplant 12: 489-503.
100. Annesley TM, Hunter BC, Fidler DR, Giacherio DA. 1995. Stability of tacrolimus (FK 506) and cyclosporine G in whole blood. Ther Drug Monit 17: 361-5.
101. Alak AM, Lizak P. 1996. Stability of FK506 in blood samples. Ther Drug Monit 18: 209-11.
102. Freeman DJ, Stawecki M, Howson B. 1995. Stability of FK 506 in whole blood samples. Ther Drug Monit 17: 266-67.
103. Holt DW. 2002. Therapeutic drug monitoring of immunosuppressive drugs in kidney transplantation. Curr Opin Nephrol Hypertens 11: 657-63.
104. Staatz CE, Tett SE. 2004. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplant. Clin Pharmacokinet 43: 623-53.
105. Wong KM, Shek CC, Chau KF, Li CS. 2000. Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients. Am J Kidney Dis 35: 660-66.
106. McAlister VC, Mahalati K, Peltekian KM, Fraser A, MacDonald AS. 2002. A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration. Ther Drug Monit 24: 346-50.
107. Lensmeyer GL, Poquette MA. 2001. Therapeutic monitoring of tacrolimus concentrations in blood: semi-automated extraction and liquid chromatography-electrospray ionization mass spectrometry. Ther Drug Monit 23: 239-49.
108. Keevil BG, McCann SJ, Cooper DP, Morris MR. 2002. Evaluation of a rapid micro-scale assay for tacrolimus by liquid chromatography-tandem mass spectrometry. Ann Clin Biochem 39: 487-92.
109. Deters M, Kirchner G, Rewsch K, Kaever V. 2002. Simultaneous quantification of sirolimus, everolimus, tacrolimus and cyclosporine by liquid chromatography-mass spectrometry (LM-MS). Clin Chem Lab Med 40: 285-92.
110. Iwasaki K, Shiraga T, Matsuda H, Nagase K, Tokuma Y, Hata T et al. 1995. Fujioka M. Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites oxidized at multiple sites of FK506. Drug Metab Dispos 23: 28-34.
111. ® Tacrolimus Assay (package insert). Microgenics Corporation, Fremont, CA, 2005.
112. Staatz CE, Taylor PJ, Tett SE. 2002. Comparison of an ELISA and an LC/MS/MS method for measuring tacrolimus concentrations and making dosage decisions in transplant recipients. Ther Drug Monit 24: 607-15.
113. Gonschior AK, Christians U, Winkler M, Linck A, Baumann J, Sewing KF. 1996. Tacrolimus (FK506) metabolite patterns in blood from liver and kidney transplant patients. Clin Chem 42: 1426-32.
114. LeGatt DF, Shalapay CE, Cheng SB. 2004. The EMIT 2000 tacrolimus assay: an application protocol for the Beckman Synchron LX20 PRO analyzer. Clin Biochem 37: 1022-30.
115. Oellerich M, Armstrong VW, Schutz E, Shaw LM. 1998. Therapeutic drug monitoring of cyclosporine and tacrolimus. Clin Biochem 31: 309-16.
116. Cogill JL, Taylor PJ, Westley IS, Morris RG, Lynch SV, Johnson AG. 1998. Evaluation of the tacrolimus II microparticle enzyme immunoassay (MEIA II) in liver and renal transplant recipients. Clin Chem 44: 1942-46.
117. Busuttil RW, Klintmalm GB, Lake JR, Miller CM, Porayko M. 1996. General guidelines for the use of tacrolimus in adult liver transplant patients. Transplantation 61: 845-47.
118. Schambeck CM, Bedel A, Keller F. 1998. Limit of quantification (functional sensitivity) of the new IMx tacrolimus II microparticle enzyme immunoassay. Clin Chem 44: 2217.
119. Tacrolimus II (package insert). Abbott Laboratories, Diagnostics Division, Abbott Park, IL, 2003.
120. Homma M, Tomita T, Yuzawa K, Takada Y, Kohda Y. 2002. False positive blood tacrolimus concentration in microparticle enzyme immunoassay. Biol Pharm Bull 25: 1119-20.
121. Kahn SE, Vazquez P, Meyer P, Dickson D, Schmidt E, Castellani W, et al. 2008. Analytical multi-site evaluation of the Abbott ARCHITECT tacrolimus assay. Clin Chem 54(suppl): A19 (abstract).
122. Kuzuya T, Ogura Y, Motegi Y, Moriyama N, Nabeshima T. 2002. Interference of hematocrit in the tacrolimus II microparticle enzyme immunoassay. Ther Drug Monit 24: 507-11.
123. Akbas SH, Ozdem S, Caglar S, Tuncer M, Gurkan A, Yucetin L. et al. 2005. Effects of some hematological parameters on whole blood tacrolimus concentration measured by two immunoassay-based analytical methods. Clin Biochem 38: 552-57.
124. Ghoshal AK, Soldin SJ. 2002. IMx tacrolimus II assay: is it reliable at low blood concentrations? A comparison with tandem MS/MS. Clin Biochem 35: 389-92.
125. Steele BW, Wang E, Soldin SJ, Klee G, Elin RJ, Witte DL. 2003. A longitudinal replicate study of immunosuppressive drugs. A College of American Pathologists Study. Arch Pathol Lab Med 127: 283-88.
126. Miller JL. 1999. Sirolimus approved with renal transplant indication. Am J Health Syst Pharm 56: 2177-78.
127. Sedrani R, Cottens S, Kallen J, Schuler W. 1998. Chemical modification of rapamycin: the discovery of SZD RAD. Transplant Proc 30: 2192-94
128. Abraham RT, Wiederrecht GJ. 1996. Immunopharmacology of rapamycin. Ann Rev Immunol 14: 483-510.
129. Kimball PM, Derman RK, Van Buren CT, Lewis RM, Katz S, Kahan BD. 1993. Cyclosporine and rapamycin affect protein kinase C induction of intracellular activation signal, activator of DNA replication. Transplantation 55: 1128-32.
130. Mahalati K, Kahan BD. 2001. Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet 40: 573-85.
131. Zimmerman JJ, Kahan BD. 1997. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol 37: 405-15.
132. Yatscoff RW, Boeckx R, Holt DW, Kahan BD, LeGatt DF, Sehgal S et al. 1995. Consensus guidelines for therapeutic drug monitoring of rapamycin: report of the consensus panel. Ther Drug Monit 17: 676-80.
133. Cattaneo D, Merlini S, Pellegrino M, Carrara F, Zenoni S, Murgia S, Baldelli S et al. 2004. Therapeutic drug monitoring of sirolimus: effect of concomitant immunosuppressive therapy and optimization of drug dosing. Am J Transplant 4: 1345-51.
134. Yatscoff R, LeGatt D, Keenan R, Chackowsky P. 1993. Blood distribution of rapamycin. Transplantation 56: 1202-6.
135. Sattler M, Guengerich FP, Yun CH, Christians U, Sewing KF. 1992. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 20: 753-61.
136. Gallant-Haidner HL, Trepanier DJ, Freitag DG, Yatscoff RW. 2000. Pharmacokinetics and metabolism of sirolimus. Ther Drug Monit 22: 31-35.
137. Leung LY, Zimmeman J, Lim HK. 1997. Metabolic disposition of [14C]-rapamycin (sirolimus) in healthy male subjects after a single oral dose. Proceedings of the International Society for the Study of Xenobiotics 12: 26 (abstract).
138. Montalbano M, Neff GW, Yamashiki N, Meyer D, Bettiol M, Slapak-Green G et al. 2004. A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus related complications. Transplantation 78: 264-68.
139. Haydar AA, Denton M, West A, Rees J, Goldsmith DJ. 2004. Sirolimus-induced pneumonitis: three cases and a review of the literature. Am J Transplant 4: 137-39.
140. Kaplan B, Meier-Kriesche HU, Napoli KL, Kahan BD. 1998. The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent. Clin Pharmacol Ther 63: 48-53.
141. Jones K, Saadat-Lajevardi S, Lee T, Horwatt R, Hicks D, Johnston A, Holt DW. 2000. An immunoassay for the measurement of sirolimus. Clin Therapeutics 22(suppl): B49-B61.
142. Salm P, Tresillian MJ, Taylor PJ, Pillans PI. 2000. Stability of sirolimus (rapamycin) in whole blood. Ther Drug Monit 22: 423-26.
143. Yatscoff RW, Faraci C, Bolingbroke P. 1992. Measurement of rapamycin in whole blood using reversephase high-performance liquid chromatography. Ther Drug Monit 14: 138-41.
144. Kahan BD, Napoli KL, Kelly PA, Podbielski J, Hussein I, Urbauer DL. 2000. Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity. Clin Transplant 14: 97-109.
145. Holt DW, Denny K, Lee TD, Johnston A. 2003. Therapeutic monitoring of sirolimus: its contribution to optimal prescription. Transplant Proc 35(suppl 3): 157S-161S.
146. Kahn SE, Vazquez D, Meyer P, Dickson D, Kenney D, Edwards M, et al. 2008. Analytical evaluation of the Abbott ARCHTECT sirolimus assay. Clin Chem 54(suppl): A14 (abstract).
147. Napoli KL, Kahan BD. 1996. Routine clinical monitoring of sirolimus (rapamycin) whole-blood concentrations by HPLC with ultraviolet detection. Clin Chem 42: 1943-48.
148. Napoli KL. 2000. A practical guide to the analysis of sirolimus using high-performance liquid chromatography with ultraviolet detection. Clin Ther 22(suppl): B14-B24.
149. Maleki S, Graves S, Becker S, Horwatt R, Hicks D, Stroshane RM, Kincaid H. 2000. Therapeutic monitoring of sirolimus in human whole-blood samples by high-performance liquid chromatography. Clin Ther 22(suppl): B25-B37.
150. Wang S, Miller A. 2008. A rapid liquid chromatography-tandem mass spectrometry analysis of whole blood sirolimus using turbulent flow technology for online extraction. Clin Chem Lab Med 46: 1631-34.
151. Wilson D, Johnston F, Holt D, Moreton M, Engelmayer J, Gaulier J-M et al. 2006. Multi-center evaluation of analytical performance of the microparticle enzyme immunoassay for sirolimus. Clin Biochem 39: 378-86.
152. ® Sirolimus Assay (package insert). Microgenics Corporation, Fremont, CA, 2004.
153. Vicente FB, Smith FA, Peng Y, Wang S. 2006. Evaluation of an immunoassay of whole blood sirolimus in pediatric transplant patients in comparison with high-performance liquid chromatography/tandem mass spectrometry. Clin Chem Lab Med 44: 497-99.
154. Holt DW, Laamanen MK, Johnston A. 2005. A microparticle enzyme immunoassay to measure sirolimus. Transplant Proc 37: 182-84.
155. Zochowska D, Bartlomiejczyk I, Kaminska A, Senatorski G, Paczek L. 2006. High-performance liquid chromatography versus immunoassay for the measurement of sirolimus: comparison of two methods. Transplant Proc 38: 78-80.
156. Fillee C, Mourad M, Squifflet JP, Malaise J, Lerut J, Reding R et al. 2005. Evaluation of a new immunoassay to measure sirolimus blood concentrations compared to a tandem mass-spectrometric chromatographic analysis. Transplant Proc 37: 2890-91.
157. ® assay with HPLC-MS/MS for the determination of whole-blood sirolimus from transplant recipients. Ther Drug Monit 28: 164-68.
158. ® sirolimus assay compared with HPLC-MS/MS and HPLC-UV in transplant recipient specimens. Ther Drug Monit 27: 309-14.
159. Holt DW, McKeown DA, Lee TD, Hicks D, Cal P, Johnston A. 2004. The relative proportions of sirolimus metabolites in blood using HPLC with mass-spectrometric detection. Transplant Proc 36: 3223-25.
160. Christians U, Jacobsen W, Serkova N, Benet LZ, Vidal C, Sewing KF. Et al. 2000. Automated, fast and sensitive quantification of drugs in blood by liquid chromatography-mass spectrometry with on-line extraction: immunosuppressants. J Chromatogr B Biomed Sci Appl 748: 41-53.
161. Holt DW, Lee T, Jones K, Johnston A. 2000. Validation of an assay for routine monitoring of sirolimus using HPLC with mass spectrometric detection. Clin Chem 46: 1179-83.
162. Salm P, Taylor PJ, Pillans PI. 2000. The quantitation of sirolimus by high-performance liquid chromatography-tandem mass spectrometry and microparticle enzyme immunoassay in renal transplant recipients. Clin Ther 22(suppl): B71-B85.
163. Kirchner GI, Meier-Wiedenbach I, Manns MP. 2004. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 43: 83-95.
164. Hoyer PF, Ettenger R, Kovarik JM, Webb NJ, Lemire J, Mentser M et al. 2003. Everolimus Pediatric Study Group. Everolimus in pediatric de nova renal transplant patients. Transplantation 75: 2082-85.
165. Kahan BD, Kaplan B, Lorber MI, Winkler M, Cambon N, Boger RS. 2001. RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection. Transplantation 71: 1400-6.
166. Kovarik JM, Kahan BD, Kaplan B, Lorber M, Winkler M, Rouilly M et al. 2001. Everolimus Phase 2 Study Group. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin Pharmacol Ther 69: 48-56.
167. Kahan BD, Podbielski J, Napoli KL, Katz SM, Meir-Kriesche HU, Van Buren CT. 1998. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 66: 1040-46.
168. Nashan B. 2002. Review of the proliferation inhibitor everolimus. Expert Opin Investig Drug 11: 1842-50.
169. Kirchner GI, Winkler M, Mueller L, Vidal C, Jacobsen W, Franzke A. 2000. Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD. Br J Clin Pharmacol 50: 449-54.
170. ® Assay System (package insert). Seradyn Inc, Indianapolis, IN, 2003.
171. Lehmkuhl H, Ross H, Eisen H, Valantine H. 2005. Everolimus (Certican) in heart transplantation: optimizing renal function through minimizing cyclosporine exposure. Transplant Proc 37: 4145-49.
172. Salm P, Warnholtz C, Boyd J, Arabshahi L, Marbach P, Taylor PJ. 2006. Evaluation of a fluorescent polarization immunoassay for whole blood everolimus determination using samples from renal transplant recipients. Clin Biochem 39: 732-38.
173. Baldelli S, Murgia S, Merlini S, Zenoni S, Perico N, Remuzzi G, Cattaneo D. 2005. High-performance liquid chromatography with ultraviolet detection for therapeutic drug monitoring of everolimus. J Chromatogr B 816: 99-105.
174. Salm P, Taylor PJ, Lynch SV, Pillans PI. 2002. Quantification and stability of everolimus (SDZ RAD) in human blood by high-performance liquid chromatography-electrospray tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci 772: 283-90.
175. Quinn CM, Bugeja VC, Gallagher JA, Whittaker PA. 1990. The effect of mycophenolic acid on the cell cycle of Candida abicans. Mycopathologia 111: 165-68.
176. Lee WA, Gu L, Miksztal AR, Chu N, Leung K, Nelson PH. 1990. Bioavailability improvement of mycophenolic acid through amino ester derivatization. Pharm Res 7: 161-66.
177. Franklin TJ, Cook JM. 1969. The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem J 113: 515-24.
178. Wu JC. 1994. Mycophenolate mofetil: molecular mechanisms of action. Perspect Drug Discov Design 2: 185-204.
179. Eugui EM, Allison A. 1993. Immunosuppressive activity of mycophenolate mofetil. Ann NY Acad Sci 685: 309-29.
180. Allison AC, Eugui EM. 1996. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant 10: 77-84.
181. Bullingham R, Monroe S, Nicholls A, Hale M. 1996. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol 36: 315-24.
182. Bullingham RE, Nicholls AJ, Kamm BR. 1998. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 34: 429-55.
183. Nowak I, Shaw LM. 1995. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem 41: 1011-17.
184. Korecka M, Nikolic D, van Breemen RB, Shaw LM. 1999. Inhibition of inosine monophosphate dehydrogenase by mycophenolic acid glucuronide is attributable to the presence of trace quantities of mycophenolic acid. Clin Chem 45: 1047-50.
185. Shipkova M, Armstrong VW, Wieland E, Niedmann PD, Schutz E, Brenner-Weiss G et al. 1999. Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br J Pharmacol 126: 1075-82.
186. Wieland E, Shipkova M, Schellhaas U, Schutz E, Niedmann PD, Armstrong VW, Oellerich M. 2000. Induction of cytokine release by acyl glucuronide of mycophenolic acid: a link to side effects? Clin Biochem 33: 107-13.
187. Shaw LM, Korecka M, van Breeman R, Nowak I, Brayman KL. 1998. Analysis, pharmacokinetics and therapeutic drug monitoring of mycophenolic acid. Clin Biochem 31: 323-28.
188. Kaplan B, Meier-Kriesche HU, Friedman G, Mulgaonkar S, Gruber S, Korecka M et al. 1999. The effect of renal insufficiency on mycophenolic acid protein binding. J Clin Pharmacol 39: 715-20.
189. Holt DW. 2002. Monitoring mycophenolic acid. Ann Clin Biochem 39: 173-83.
190. Mourad M, Malaise J, Chaib Eddour D, De Meyer M, Konig J, Schepers R, Squifflet JP, Wallemacq P. 2001. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. Clin Chem 47: 1241-48.
191. Sollinger HW. 2004. Mycophenolates in transplantation. Clin Transplant 18: 485-92.
192. Vidal E, Cantarell C, Capdevila L, Monforte V, Roman A, Pou L. 2000. Mycophenolate mofetil pharmacokinetics in transplant patients receiving cyclosporine or tacrolimus in combination therapy. Pharmacol Toxicol 87: 182-84.
193. Shipkova M, Armstrong VW, Kuypers D, Perner F, Fabrizi V, Holzer H, Wieland E, Oellerich M. 2001. MMF Creeping Creatinine Study Group. Ther Drug Monit 23: 717-21.
194. Schmidt LE, Rasmussen A, Norrelykke MR, Poulsen HE, Hansen BA. 2001. The effect of selective bowel decontamination on the pharmacokinetics of mycophenolate mofetil in liver transplant recipients. Liver Transplant 7: 739-42.
195. Undre NA, van Hooff J, Christiaans M, Vanrenterghem Y, Donck J, Heeman U et al. 1998. Pharmacokinetics of FK 506 and mycophenolic acid after the administration of a FK 506-based regimen in combination with mycophenolate mofetil in kidney transplantation. Transplant Proc 30: 1299-302.
196. Vietri M, Pietrabissa A, Mosca F, Pacifici GM. 2000. Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. Eur J Clin Pharmacol 56: 659-64.
197. Kato R, Ooi K, Ikura-Mori M, Tsuchishita Y, Hashimoto H, Yoshimura H et al. 2002. Impairment of mycophenolate mofetil absorption by calcium polycarbophil. J Clin Pharmacol 42: 1275-80.
198. Shaw LM, Holt DW, Oellerich M, Meiser B, van Gelder T. 2001. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit 23: 305-15.
199. Tsina I, Chu F, Hama K, Kaloostian M, Tam YL, Tarnowski T, Wong B. 1996. Manual and automated (robotic) high-performance liquid chromatography methods for the determination of mycophenolic acid and its glucuronide conjugate in human plasma. J Chromatogr B 675: 119-29.
200. Streit F, Shipkova M, Armstrong VW, Oellerich M. 2004. Validation of a rapid and sensitive liquid chromatography-tandem mass spectrometry method for free and total mycophenolic acid. Clin Chem 50: 152-59.
201. Saunders DA. 1997. Simple method for the quantitation of mycophenolic acid in human plasma. J Chromatogr B Biomed Sci Appl 704: 379-82.
202. Tsina I, Kaloostian M, Lee R, Tarnowski T, Wong B. 1996. High-performance liquid chromatographic method for the determination of mycophenolate mofetil in human plasma. J Chromatogr B 681: 347-53.
203. Shipkova M, Armstrong VW, Kiehl MG, Niedmann PD, Schutz E, Oellerich M, Wieland E. 2001. Quantification of mycophenolic acid in plasma samples collected during and immediately after intravenous administration of mycophenolate mofetil. Clin Chem 47: 1485-88.
204. Mahalati K, Kahan BD. 2005. Pharmacological surrogates of allograft outcome. Ann Transplant 5: 14-23.
205. Filler G, Mai I. 2000. Limited sampling strategy for mycophenolic acid area under the curve. Ther Drug Monit 22: 169-73.
206. Pawinski T, Hale M, Korecka M, Fitzsimmons WE, Shaw LM. 2002. Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients with concomitant tacrolimus. Clin Chem 48: 1497-504.
207. Le Guellec C, Buchler M, Giraudeau B, Le Meur Y, Gakoue JE, Lebranchu Y, Marquet P, Paintaud G. 2002. Simultaneous estimation of cyclosporin and mycophenolic acid areas under the curve in stable renal transplant patients using a limited sampling strategy. Eur J Clin Pharmacol 57: 805-11.
208. van Gleder T, Shaw LM. 2005. The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation 80(suppl 2): S244-253.
209. Brunet M, Cirera I, Martorell J, Vidal E, Millan O, Jimenez O, Rojo I, Londono MC, Rimola A. 2006. Sequential determination of pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil. Transplantation 81: 541-46.
210. van Gelder T, Meur YL, Shaw LM, Oellerich M, DeNofrio D, Holt C et al. 2006. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 28: 145-54.
211. Domke I, Engelmayer J, Langmann T, Liebisch G, Streit F, Luthe H, Dorn A, Schmitz G, Oellerich M. 2005. Measurement of total and free mycophenolic acid with new enzyme receptor methods on COBAS INTEGRA Systems. Clin Chem 51(suppl): A148 (abstract).
212. Bunch DR, Wang S. 2008. Therapeutic drug monitoring of plasma and serum mycophenolic acid by Roche Integra 400 in comparison with a high performance liquid chromatography method. Clin Chem 54(suppl): A10 (abstract).
213. Teshima D, Kitagawa N, Otsubo K, Makino K, Itoh Y, Oishi R. 2002. Simple determination of mycophenolic acid in human serum by column-switching high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 780: 21-6.
214. Sparidans RW, Hoetelmans RM, Beijnen JH. 2001. Liquid chromatographic assay for simultaneous determination of abacavir and mycophenolic acid in human plasma using dual spectrophotometric detection. J Chromatogr B Biomed Sci Appl 750: 155-61.
215. Renner UD, Thiede C, Bornhauser M, Ehninger G, Thiede HM. 2001. Determination of mycophenolic acid and mycophenolate mofetil by high-performance liquid chromatography using postcolumn derivatization. Anal Chem 73: 41-46.
216. Jain A, Venkataramanan R, Hamad IS, Zuckerman S, Zhang S, Lever J, Warty VS, Fung JJ. 2001. Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus. J Clin Pharmacol 41: 268-76.
217. Weber LT, Shipkova M, Armstrong VW, Wagner N, Schutz E, Mehls O et al. 2002. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German Study Group on Mycophenolate Mofetil Therapy. J Am Soc Nephrol 13: 759-68.
218. ® Clinical Chemistry System. Clin Chem 52(suppl): A63 (abstract).
219. ® mycophenolic acid assay on the Hitachi 911, Olympus AU640, and MGC 240 Clinical Chemistry Analyzers. Clin Chem 52(suppl): A67 (abstract).
220. Shipkova M, Schutz E, Armstrong VW, Niedmann PD, Weiland E, Oellerich M. 1999. Overestimation of mycophenolic acid by EMIT correlates with MPA metabolite. Transplant Proc 31: 1135-37.
221. Weber LT, Shipkova M, Armstrong VW, Wagner N, Schutz E, Mehls O, Zimmerhackl LB, Oellerich M, Tonshoff B. 2002. Comparison of the EMIT immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy. Clin Chem 48: 517-25.
222. Beal JL, Jones CE, Taylor PJ, Tett SE. 1998. Evaluation of an immunoassay (EMIT) for mycophenolic acid in plasma from renal transplant recipients compared with a high-performance liquid chromatography assay. Ther Drug Monit 20: 685-90.
223. Schutz E, Shipkova M, Armstrong VW, Niedmann PD, Weber L, Tonshoff B et al. 1998. Therapeutic drug monitoring of mycophenolic acid: comparison of HPLC and immunoassay reveals new MPA metabolites. Transplant Proc 30: 1185-87.
224. Westley IS, Sallustio BC, Morris RG. 2005. Validation of a high-performance liquid chromatography method for the measurement of mycophenolic acid and its glucuronide metabolites in plasma. Clin Biochem 38: 824-29.
225. Premaud A, Rousseau A, Le Meur Y, Lachatre G, Marquet P. 2004. Comparison of liquid chromatography-tandem mass spectrometry with a commercial enzyme-multiplied immunoassay for the determination of plasma MPA in renal transplant recipients and consequences for therapeutic drug monitoring. Ther Drug Monit 26: 609-19.
226. Schutz E, Shipkova M, Armstrong VW, Wieland E, Oellerich M. 1999. Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Clin Chem 45: 419-22.
227. Oellerich M, Shipkova M, Schutz E, Wieland E, Weber L, Tonshoff B, Armstrong VW. 2000. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Ther Drug Monit 22: 20-26.
228. Shaw LM, Korecka M, Aradhye S, Grossman R, Bayer L, Innes C. et al. 2000. Mycophenolic acid area under the curve values in African American and Caucasian renal transplant patients are comparable. J Clin Pharmacol 40: 624-33.
229. Mandla R, Line PD, Midtvedt K, Bergan S. 2003. Automated determination of free mycophenolic acid and its glucuronide in plasma from renal allograft recipients. Ther Drug Monit 25: 407-14.